Larimar Therapeutics Valuation
| LRMR Stock | USD 3.38 0.12 3.68% |
At this time, the firm appears to be undervalued. Larimar Therapeutics secures a last-minute Real Value of $7.44 per share. The latest price of the firm is $3.38. Our model forecasts the value of Larimar Therapeutics from analyzing the firm fundamentals such as Current Valuation of 52.87 M, return on equity of -0.51, and Shares Owned By Insiders of 1.40 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Larimar Therapeutics' valuation include:
Undervalued
Today
Please note that Larimar Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Larimar Therapeutics is based on 3 months time horizon. Increasing Larimar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Larimar stock is determined by what a typical buyer is willing to pay for full or partial control of Larimar Therapeutics. Since Larimar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Larimar Stock. However, Larimar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.38 | Real 7.44 | Target 20.41 | Hype 3.75 | Naive 3.6 |
The intrinsic value of Larimar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Larimar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Larimar Therapeutics helps investors to forecast how Larimar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Larimar Therapeutics more accurately as focusing exclusively on Larimar Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Larimar Therapeutics' intrinsic value based on its ongoing forecasts of Larimar Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Larimar Therapeutics' closest peers.
Larimar Therapeutics Cash |
|
Larimar Valuation Trend
Larimar Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Larimar Therapeutics' financial worth over time. Using both Larimar Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Larimar Therapeutics Total Value Analysis
Larimar Therapeutics is now expected to have valuation of 52.87 M with market capitalization of 208.73 M, debt of 5.12 M, and cash on hands of 54.92 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Larimar Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
52.87 M | 208.73 M | 5.12 M | 54.92 M |
Larimar Therapeutics Asset Utilization
One of the ways to look at asset utilization of Larimar is to check how much profit was generated for every dollar of assets it reports. Larimar Therapeutics secures a negative usage of assets of -0.31 %, losing $0.003147 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Larimar Therapeutics shows how discouraging it operates for each dollar spent on its assets.Larimar Therapeutics Ownership Allocation
The majority of Larimar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Larimar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Larimar Therapeutics. Please pay attention to any change in the institutional holdings of Larimar Therapeutics as this could imply that something significant has changed or is about to change at the company.Larimar Therapeutics Profitability Analysis
Net Loss for the year was (80.6 M) with profit before overhead, payroll, taxes, and interest of 0.About Larimar Therapeutics Valuation
The stock valuation mechanism determines Larimar Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Larimar Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Larimar Therapeutics. We calculate exposure to Larimar Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Larimar Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -279.9 K | -265.9 K |
Larimar Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Larimar Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 61.3 M |
Larimar Therapeutics Current Valuation Indicators
Larimar Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Larimar Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Larimar Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Larimar Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Larimar Therapeutics' worth.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.